Trial Profile
A Phase II Single Arm Study of Nivolumab as Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Hodgkin Lymphoma at Risk of Relapse or Progression
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Jun 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions
- 08 Jun 2023 Status changed from active, no longer recruiting to completed.
- 10 May 2022 Status changed from recruiting to active, no longer recruiting.
- 04 Feb 2022 Planned primary completion date changed from 1 Feb 2022 to 1 Jun 2022.